Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...

NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

As they prepare for Phase One clinical trials, Corsair Pharma is prioritizing safety, tolerability, and quality at every stage of development. To support these critical goals, the company has ...

A new molecular imaging technique-18F-FAPI PET-can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker ...

NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

Orthofix Medical Inc. , a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, February 25, 2025 before ...

Atalanta Therapeutics is pioneering RNA interference (RNAi) for the treatment of neurological diseases, having developed a proprietary platform that, for the first time enables RNAi to be deployed as ...